MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) has appointed Ali Soleymannezhad as Chief Commercial Officer, effective September 11, 2024. In his new role, Soleymannezhad will lead MaxCyte's commercial operations to increase adoption of the ExPERT Platform and expand the company's market impact in Cell and Gene Therapy. Previously, he served as Executive Vice President of Bioprocessing at MaxCyte, leading global product development and marketing strategy for the bioprocessing business.
Soleymannezhad brings 20 years of technical sales, marketing, and product development experience to his new role. Prior to joining MaxCyte, he held executive positions at Tosoh Bioscience, including Executive Vice President for the Separations and Purification business, overseeing a team of 140 employees across four global sites. MaxCyte's CEO, Maher Masoud, expressed confidence in Soleymannezhad's ability to drive future growth for the company.
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) ha nominato Ali Soleymannezhad come Chief Commercial Officer, con effetto dall'11 settembre 2024. Nel suo nuovo ruolo, Soleymannezhad guiderà le operazioni commerciali di MaxCyte per aumentare l'adozione della piattaforma ExPERT e ampliare l'impatto dell'azienda nel mercato della terapia cellulare e genica. In precedenza, ha ricoperto il ruolo di Vice Presidente Esecutivo del Bioprocessing presso MaxCyte, guidando lo sviluppo globale dei prodotti e la strategia di marketing per il business del bioprocessing.
Soleymannezhad porta con sé 20 anni di esperienza nelle vendite tecniche, nel marketing e nello sviluppo prodotto. Prima di unirsi a MaxCyte, ha ricoperto posizioni dirigenziali presso Tosoh Bioscience, incluso il ruolo di Vice Presidente Esecutivo per il business delle Separazioni e Purificazioni, supervisionando un team di 140 dipendenti distribuiti in quattro sedi globali. Il CEO di MaxCyte, Maher Masoud, ha espresso fiducia nella capacità di Soleymannezhad di guidare la crescita futura dell'azienda.
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) ha nombrado a Ali Soleymannezhad como Director Comercial, con efecto a partir del 11 de septiembre de 2024. En su nuevo rol, Soleymannezhad liderará las operaciones comerciales de MaxCyte para aumentar la adopción de la plataforma ExPERT y expandir el impacto de la empresa en la terapia celular y génica. Anteriormente, se desempeñó como Vicepresidente Ejecutivo de Bioprocesamiento en MaxCyte, liderando el desarrollo de productos globales y la estrategia de marketing para el negocio de bioprocesamiento.
Soleymannezhad aporta 20 años de experiencia en ventas técnicas, marketing y desarrollo de productos a su nuevo puesto. Antes de unirse a MaxCyte, ocupó cargos ejecutivos en Tosoh Bioscience, incluido el de Vicepresidente Ejecutivo para el negocio de Separaciones y Purificación, supervisando un equipo de 140 empleados en cuatro sitios globales. El CEO de MaxCyte, Maher Masoud, expresó su confianza en la capacidad de Soleymannezhad para impulsar el crecimiento futuro de la empresa.
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT)는 Ali Soleymannezhad를 최고 상업 책임자로 임명했습니다, 2024년 9월 11일부터 효력이 발생합니다. 새 역할에서 Soleymannezhad는 MaxCyte의 상업 운영을 이끌어 ExPERT 플랫폼의 채택을 증가시키고 세포 및 유전자 치료 시장에서 회사의 영향력을 확장할 것입니다. 이전에는 MaxCyte에서 생물 처리의 부사장으로 재직하며 생물 처리 비즈니스의 글로벌 제품 개발 및 마케팅 전략을 이끌었습니다.
Soleymannezhad는 기술 판매, 마케팅 및 제품 개발 분야에서 20년의 경험을 새 역할에 가져옵니다. MaxCyte에 합류하기 전에는 Tosoh Bioscience에서 여러 경영직을 맡았으며, 여기에는 분리 및 정제 비즈니스의 부사장을 포함해 전 세계 4개 지사에 걸쳐 140명의 팀을 이끌었습니다. MaxCyte의 CEO인 Maher Masoud는 Soleymannezhad가 향후 회사 성장에 기여할 수 있다고 믿고 있습니다.
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) a nommé Ali Soleymannezhad au poste de Directeur Commercial, prenant effet le 11 septembre 2024. Dans son nouveau rôle, Soleymannezhad dirigera les opérations commerciales de MaxCyte pour accroître l'adoption de la plateforme ExPERT et élargir l'impact de l'entreprise dans le secteur de la thérapie cellulaire et génique. Auparavant, il a été Vice-Président Exécutif du Bioprocessing chez MaxCyte, supervisant le développement de produits à l'échelle mondiale et la stratégie marketing pour le secteur du bioprocessing.
Soleymannezhad apporte 20 ans d'expérience dans les ventes techniques, le marketing et le développement de produits à son nouveau rôle. Avant de rejoindre MaxCyte, il a occupé des postes de direction chez Tosoh Bioscience, y compris celui de Vice-Président Exécutif pour le secteur des séparations et purifications, supervisant une équipe de 140 employés sur quatre sites à l'échelle mondiale. Le PDG de MaxCyte, Maher Masoud, a exprimé sa confiance dans la capacité de Soleymannezhad à stimuler la croissance future de l'entreprise.
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) hat Ali Soleymannezhad zum Chief Commercial Officer ernannt, mit Wirkung zum 11. September 2024. In seiner neuen Rolle wird Soleymannezhad die kommerziellen Aktivitäten von MaxCyte leiten, um die Akzeptanz der ExPERT-Plattform zu erhöhen und die Marktpräsenz des Unternehmens in der Zell- und Gentherapie auszubauen. Zuvor war er als Executive Vice President für Bioprocessing bei MaxCyte tätig und leitete die globale Produktentwicklung sowie die Marketingstrategie für das Bioprocessing-Geschäft.
Soleymannezhad bringt 20 Jahre Erfahrung in technischen Vertriebs-, Marketing- und Produktentwicklungsbereichen in seine neue Position ein. Vor seiner Tätigkeit bei MaxCyte hatte er Führungspositionen bei Tosoh Bioscience inne, dort war er unter anderem Executive Vice President für den Bereich Trennung und Reinigung und leitete ein Team von 140 Mitarbeitern an vier globalen Standorten. Maher Masoud, CEO von MaxCyte, äußerte sein Vertrauen in die Fähigkeit von Soleymannezhad, das zukünftige Wachstum des Unternehmens voranzutreiben.
- Appointment of experienced executive Ali Soleymannezhad as Chief Commercial Officer
- Potential for increased adoption of ExPERT Platform and market expansion in Cell and Gene Therapy
- 20 years of industry experience in technical sales, marketing, and product development
- None.
ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024.
In his new role, Mr. Soleymannezhad will lead MaxCyte’s commercial operations to increase adoption of the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to customers, and expand the Company’s market impact in Cell and Gene Therapy. Prior to his role as Chief Commercial Officer, Mr. Soleymannezhad was the Executive Vice President of Bioprocessing, where he led global product development and marketing strategy for MaxCyte’s bioprocessing business.
“I am delighted to promote Ali to the role of Chief Commercial Officer,” said Maher Masoud, President and CEO of MaxCyte. “His diverse experience, skills, and leadership at MaxCyte as Executive Vice President of Bioprocessing have strengthened our organization’s product development and commercial strategies. We look forward to working alongside Ali as he leads our commercial efforts to drive future growth at MaxCyte.”
Mr. Soleymannezhad brings 20 years of technical sales, marketing, and product development experience to his new role. Prior to Executive Vice President of Bioprocessing at MaxCyte, he served as Executive Vice President for the Separations and Purification business at Tosoh Bioscience and oversaw a team of 140 employees across four global manufacturing, development, and commercial sites. Mr. Soleymannezhad was also Vice President of Global Marketing and Business Development and Director of Sales and Marketing-Americas at Tosoh and served on the board of Semba Biosciences.
“I am excited to apply my experience in sales and marketing and global business strategy to MaxCyte’s commercial efforts,” said Ali Soleymannezhad, CCO of MaxCyte. “I look forward to working with our executive team to continue MaxCyte’s commitment to supporting our customer’s Cell and Gene therapy work in research, through the clinic, and beyond.”
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements about us and our industry involve substantial known and unknown risks, uncertainties, and assumptions that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements include, but are not limited to, statements about the Company’s projected full-year total revenue, core revenue, and SPL program revenue and statements about possible or future results of operations or financial position. In some cases, you can identify forward-looking statements because they contain words such as "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," “expect,” "estimate," “seek,” "predict," “future,” "project," "potential," "continue," “contemplate,” "target,” the negative of these words and similar words or expressions. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. The forward-looking statements contained in this press release, include, without limitation, statements concerning the following: our expected future growth and success of our business model; the size and growth potential of the markets for our products, and our ability to serve those markets, increase our market share, and achieve and maintain industry leadership; and our ability to expand our customer base and enter into additional SPL partnerships.
These and other risks and uncertainties are described in greater detail in Item 1A , entitled "Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on or about March 12, 2024, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available through the Investor Menu, Financials section, under “SEC Filings” on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Science
Jordan Vines
jvines@spectrumscience.com
+1 540-629-3137
Nominated Adviser and Joint Corporate Broker
Panmure Liberum
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
ICR Consilium
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
FAQ
Who is the new Chief Commercial Officer of MaxCyte (MXCT)?
What is Ali Soleymannezhad's previous experience at MaxCyte (MXCT)?
What are the main responsibilities of the new CCO at MaxCyte (MXCT)?
How many years of industry experience does Ali Soleymannezhad bring to MaxCyte (MXCT)?
